GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) – Pipeline Review, H2 2017’, provides in depth analysis on GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Dermatology, Metabolic Disorders and Ophthalmology under development targeting GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects

The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Boehringer Ingelheim GmbH

Codiak BioSciences Inc

Critical Outcome Technologies Inc

Horizon Discovery Group Plc

Kyowa Hakko Kirin Co Ltd

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Nuevolution AB

PeptiDream Inc

Takeda Pharmaceutical Co Ltd

Tosk Inc

Warp Drive Bio Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Overview 8

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 15

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Companies Involved in Therapeutics Development 22

AstraZeneca Plc 22

Aurigene Discovery Technologies Ltd 22

Boehringer Ingelheim GmbH 22

Codiak BioSciences Inc 23

Critical Outcome Technologies Inc 23

Horizon Discovery Group Plc 24

Kyowa Hakko Kirin Co Ltd 24

Mirati Therapeutics Inc 24

Moderna Therapeutics Inc 25

Nuevolution AB 25

PeptiDream Inc 26

Takeda Pharmaceutical Co Ltd 26

Tosk Inc 27

Warp Drive Bio Inc 27

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Drug Profiles 28

ARS-853 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

AZD-4785 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Biologics to Inhibit KRAS for Pancreatic Cancer - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

COTI-219 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

HD-001 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

KHK-KRAS - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Krasin-100 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

KRpep-2d - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MM-41 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

mRNA-5671 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SBT-100 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

SBT-102 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SBT-200 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

SBT-300 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule to Inhibit KRAS for Oncology - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecule to Inhibit KRAS for Oncology - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules 2 to Inhibit K-Ras for Oncology - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecules to Inhibit K Ras for Oncology - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecules to Inhibit KRAS for Non-Small Cell Lung Cancer - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Inhibit KRAS for Oncology - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Inhibit KRAS for Oncology - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

SML-8731 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Vaccine to Target K-RAS for Lung Cancer - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Dormant Products 59

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC

3.6.5.2) - Product Development Milestones 60

Featured News & Press Releases 60

Nov 13, 2017: Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs 60

Dec 16, 2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer 60

Oct 11, 2016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS 61

Aug 29, 2016: FDA Grants Orphan Drug Designation to SBT-100 for Pancreatic Cancer 61

Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation 62

May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement 62

Jan 03, 2013: Kyowa Hakko Kirin Selects Second DsiRNA Therapeutic Candidate For Development, Triggering $5m Milestone Payment To Dicerna Pharma 63

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indication, H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Investigation by Universities/Institutes, H2 2017 15

Products under Investigation by Universities/Institutes, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by AstraZeneca Plc, H2 2017 22

Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 22

Pipeline by Boehringer Ingelheim GmbH, H2 2017 23

Pipeline by Codiak BioSciences Inc, H2 2017 23

Pipeline by Critical Outcome Technologies Inc, H2 2017 23

Pipeline by Horizon Discovery Group Plc, H2 2017 24

Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 24

Pipeline by Mirati Therapeutics Inc, H2 2017 25

Pipeline by Moderna Therapeutics Inc, H2 2017 25

Pipeline by Nuevolution AB, H2 2017 26

Pipeline by PeptiDream Inc, H2 2017 26

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 26

Pipeline by Tosk Inc, H2 2017 27

Pipeline by Warp Drive Bio Inc, H2 2017 27

Dormant Projects, H2 2017 59

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Top 10 Molecule Types, H2 2017 20

Number of Products by Stage and Top 10 Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports